Strides Pharma International Limited BALANCE SHEET AS AT MARCH 31, Note. USD No. ASSETS Non-current assets (a) Financial assets (i) Investments

Similar documents
Generic Partners UK Ltd BALANCE SHEET AS AT MARCH 31, Mar-17 ASSETS Non-current assets (a) Property, Plant and Equipment

Group Consolidated Income Statement

Strides Pharma Namibia BALANCE SHEET AS AT Mar 31, 2016

Strides Pharma Cameroon BALANCE SHEET AS AT Mar 31, 2016

SPC Co. Ltd Sudan BALANCE SHEET AS AT Mar 31, 2016

Current assets (a) Financial assets (i) Cash and cash equivalents 2 108,330 (b) Other current assets 3 879,348 Total current assets 987,678

\WIPRO TECHNOLOGIES SPAIN STANDALONE FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED MARCH 31, 2015

As at. As at 31-Mar-17

Arrow Pharma Pte Limited BALANCE SHEET AS AT Mar 31, 2016

As at March 31, 2016 As at April 1, 2015 Balance Sheet as at March 31, 2017 Note No. Rs. Lakhs Rs. Lakhs Rs. Lakhs Rs. Lakhs

Notes No 2014 RMB 1 1,652, ,096,459 31,749, ,410, , ,273, ,597, ,346, , , , ,793

The Siam Cement Public Company Limited and its Subsidiaries

As at. As at 31 March 2017

CONSOLIDATED FINANCIAL STATEMENTS


CONSOLIDATED FINANCIAL STATEMENTS

As at. As at 31-Mar-17

Consolidated Statement of Financial Position

EUR MILLION Q1/2018 Q1/2017 Q4/ Net sales ,232.6 Comparable EBITDA Comparable EBITDA margin, % 11.

As at March 31, 2017 Balance Sheet as at March 31, 2018 Note No. Rs. Lakhs Rs. Lakhs Rs. Lakhs

General information about company

Suzlon Wind Eberji Sanayi ve Ticaret Limited Sirketi. IND AS Financial Statements for the year ended March 31, 2018

As at March 31, 2016 As at April 1, 2015 Balance Sheet as at March 31, 2017 Note No. Rs. Lakhs Rs. Lakhs Rs. Lakhs

JUBILANT DRAXIMAGE INC., CANADA

JUBILANT PHARMA TRADING INC Balance Sheet As at 31st Mar Notes No USD INR (' In Thousands)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, Months ended September 30, 2018

Total Non Current Assets 1,210,797 4,134,177

General information about company

Via Technologies, Inc. and Subsidiaries. Consolidated Financial Statements for the Three Months Ended March 31, 2018 and 2017

PART I STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2015

General information about company

JUBILANT LIEF SCIENCES NV Balance Sheet As at 31st Mar Notes No EUR INR (' In Thousands) EUR INR (' In Thousands)

Reviewed Reviewed Not Reviewed Not Reviewed. Notes 2018

Consolidated Balance Sheet(Audited)

Principal Activities The principal activities of the company is manufacturing of products for the health and beauty industry.

YAŞAR HOLDİNG A.Ş. CONSOLIDATED INTERIM FINANCIAL STATEMENTS AT 30 SEPTEMBER 2018

XYZ PLC. Statement of Comprehensive Income (Single statement approach, analyzed by function of expense) For the year ended 31 March 2013

Accounting Title 2017/03/ /12/ /03/31 Balance Sheet

(Amount in Rs.) Particulars Note No. As at As at As at March 31, 2017 March 31, 2016 January 1, 2015

Consolidated Balance Sheets Consolidated Balance Sheet

General information about company

Elgi Compressors Europe S.r.l. Balance Sheet As At 31st March, 2018 Particulars Note March 31, 2018 March 31, 2017

(Rs. in Lacs) Statement of Unaudited Standalone Financial Results for the Quarter Ended on June 30, 2017 Quarter Ended Sr.

3 Months ended. September 30, 2018

(Rs. in Lacs) Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended September 30, 2017 Quarter Ended

Group statement of comprehensive income (IFRS) Restated

Euro ( in thousand) As at. As at 31 March 2017

Draximage Limited, Ireland Balance Sheet as at 31 March 2017

Jubilant DraxImage (USA) Inc. Balance Sheet as at 31 March 2017

Japan Display Inc. Consolidated Financial Statements March 31, 2018

Foreword by the Management Board

Balance As at ASSETS 1. Non-Current Assets a Property, plant and equipment b Other Intangible assets

WIPRO TECHNOLOGIES NORWAY AS FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED MARCH 31, 2015

Jubilant Draximage Limited Balance Sheet as at 31 March 2017 (INR in thousands) As at 31 March 2017

ADISONS PRECISION INSTRUMENTS MANUFACTURING COMPANY LIMITED BALANCE SHEET AS AT 31ST MARCH, 2016 ( `.in INR)

Accounting Title 2013/12/ /12/ /1/1 Balance Sheet

Financial Statement Balance Sheet

Elgi Compressors Italy S.r.l. Balance Sheet As At 31st March 2017

(Value in INR) BALANCE SHEET AS AT Particulars Note March 31,2017 March 31,2016 II. ASSETS

Balance Sheet as at March 31, 2017

BOUYGUES GROUP CONSOLIDATED FINANCIAL STATEMENTS

General information about company

Standalone Financial Results for the Quarter / Twelve Months ended on 31st March 2015

WIPRO NETWORKS PTE LIMITED FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED MARCH 31, 2015

Jubilant Hollister Stier Inc Balance Sheet as at 31 March 2017

PSI SUPPLY NV

Cadila Healthcare Limited

STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2017 Rs. in Lakhs Sl. No.

JIGYASA INFRASTRUCTURE LIMITED CIN

Kotkamills Group Oyj INTERIM REPORT

PARTICULARS SCHEDULE As at

Dynamic 2018 Q3 IFRS Consolidated Financial Statements

Standalone Financial Results for the Quarter ended on 30th June 2015

A P P E N D I C E S B U S I N E S S A S U N U S U A L

BOUYGUES GROUP CONSOLIDATED FINANCIAL STATEMENTS

WIPRO PROMAX ANALYTICS SOLUTIONS LLC FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED MARCH 31, 2015

ASSETS 31 December December 2014

ASSETS 31 December December 2016

ASSETS 31 March December 2017

WIPRO CORPORATE TECHNOLOGIES GHANA LIMITED FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED MARCH 31, 2015

RICHWAVE TECHNOLOGY CORPORATION

NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2016

Standalone Financial Results for the Quarter / Year ended on 31st March 2014

TOTAL ASSETS 862,452 1,723,575. Equity (a) Equity share capital (b) Other equity 6 622, ,975 Total Equity 622, ,075

PRESS RELEASE. The Board of Directors approves the Consolidated Interim Financial Report for the first half of 2016.

2016/2/25 Financial Statement Balance Sheet

The National Detergent Co. SAOG

YAŞAR HOLDİNG A.Ş. CONSOLIDATED FINANCIAL STATEMENTS AT 30 SEPTEMBER 2015

Accounting Title 2016/3/ /12/ /3/31 Balance Sheet

ASPEED TECHNOLOGY INC. AND SUBSIDIARIES

Interim Financial Statements (Un-audited) 1 st Quarter Ended September 30, 2017

Cash and cash equivalents 2,588,430 2,501,742 1,011,412 1,176,045. Fixed deposits less than one year 37,057 64,803 14,960 34,203

SAM ENGINEERING & EQUIPMENT (M) BERHAD

Xiamen C&D Inc. Consolidated Balance Sheet As at 31 December 2013

ZUARI AGRO CHEMICALS LIMITED Investors Presentation Q2 FY 2019

PAO TMK Consolidated Financial Statements Year ended December 31, 2016

JUBILANT DRUG DEVELOPMENT PTE LIMITED Balance Sheet As at 31st Mar Notes No USD INR (' In Thousands) USD INR (' In Thousands)

ERGO DESIGN PRIVATE LIMITED BALANCE SHEET AS AT 31ST MARCH, 2016

IFRS Interim Results. 25 weeks to 24 July November 2005

CONSOLIDATED FINANCIAL STATEMENTS These Consolidated Financial Statements were publicly released in the Japanese language on November 9, 2016.

Transcription:

BALANCE SHEET AS AT MARCH 31, 2017 A I II Note 31-Mar-17 31-Mar-16 ASSETS Non-current assets (a) Financial assets (i) Investments 51,383,062 51,383,062 Total Non-current assets 51,383,062 51,383,062 Current assets (a) Financial assets (ii) Cash and cash equivalents 1 568,526 36,269 (ii) Other financials assets - ST 2-13,250,384 (c) Other current assets 3 72,439 71,731 Total Current assets 640,965 13,358,383 Total Assets 52,024,027 64,741,445 B 1 EQUITY AND LIABILITIES Equity (a) Equity Share capital 4 438,000 438,000 (b) Other equity 5 24,697,421 59,758,163 Total Equity 25,135,421 60,196,163 II 1 Liabilities Current liabilities (a) Financials Liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (b) Current tax liabilities 6-2,838,749 7 47,103 19,993 8 25,148,365-9 1,693,138 1,686,540 26,888,606 4,545,282 Total Equity and liabilities 52,024,027 64,741,445 See accompanying notes forming part of the Financial Statements

Note Strides Pharma International Limited Notes forming part of the financial statements 1 Cash and cash equivalents Balance with banks in current account 568,526 36,269 Total 568,526 36,269 2 Other financial assets Loans and advances to related party - 13,250,384 Total - 13,250,384 3 Other current assets Balances with Government authorities: - VAT receivable 72,439 71,731 Total 72,439 71,731 6 Borrowings Loan from related party - 2,838,749 Total - 2,838,749 7 Trade payables Other than acceptances 47,103 19,993 Total 47,103 19,993 8 Other financial liabilities Amount in INR Due to Related Parties 25,148,365 - Total 25,148,365-9 Current tax liabilities Current tax 1,693,138 1,686,540 Total 1,693,138 1,686,540

STATEMENT OF CHANGES IN EQUITY 4 Share capital Particulars 31-Mar-17 31-Mar-16 Authorised Total Issued, subscribed and fully paid-up Equity 438,000 438,000 Preference Total 438,000 438,000

STATEMENT OF CHANGES IN EQUITY 5 Other equity Securities Premium Account Opening Balance 715,093 - Add : Premium on shares issued during the year - 715,093 Closing balance 715,093 715,093 Surplus in Statement of Profit and Loss Opening Balance 59,043,070 60,624,765 Add: On account of merger (1,410,238) Add: (Loss) for the year (35,060,742) (2,991,933) Closing balance 23,982,328 59,043,070 Share application monies pending allotemnt Opening Balance Add : Monies received during the year Less : Share issued/money refunded during the year - Closing balance Other comprehensive income Actuarial gain/(loss) on defined benefit obligation Opening Balance Add/(less): Other comprehensive income for the year Add/(less): Tax impact on the above Closing balance Total 24,697,421 59,758,163

STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2017 Note 31-Mar-17 31-Mar-16 1 Revenue from operations 2 Other income 10 12,309 207,035 3 Total revenue (1+2) 12,309 207,035 4 Expenses (a) Cost of materials consumed (b) Purchase of stock-in-trade (c) (Increase) / Decrease in inventories of finished goods, work-inprogress and stock-in-trade (a) Employee benefits expenses (b) Other expenses Total 11 64,863 214,063 64,863 214,063 5 Earning before exceptional items, interest, tax, depreciation and (52,554) (7,028) amortisation (EBITDA) (3-4) 6 Finance costs 12 1,589 2,212 7 Depreciation and amortisation expense 8 Profit before exceptional items and tax (5-6-7) (54,144) (9,240) 9 Exceptional items gain / (loss) (net) (35,000,000) (1,300,000) 10 Profit before tax (8+9) (35,054,144) (1,309,240) 11 Tax expense 13 6,598 1,682,693 12 Profit for the year (10-11) (35,060,742) (2,991,933) 13 Other Comprehensive Income A) (i) Items that will not be reclassified to profit or loss A) (ii) Income tax relating to items that will not be reclassified to profit or loss B) (i) Items that may be reclassified to profit or loss B) (ii) Income tax relating to items that may be reclassified to profit or loss Total Other comprehensive Income 14 Total Comprehensive Income for the period (12+13) (35,060,742) (2,991,933) See accompanying notes forming part of the Financial Statements

Notes forming part of the financial statements Note 13 Other income Exchange fluctuation gain (net) 12,309 - Interest Income - 122,925 Other Non Operating Income - 84,110 Total 12,309 207,035 15 Other expenses Guarantee Commission - 129,727 Rates & taxes - 786 Legal and Professional fees 51,736 75,075 Other expenses 722 - Exchange fluctuation Loss 12,405 8,476 Total 64,863 214,063 16 Finance cost Bank Charges & Commission 1,589 2,212 Total 1,589 2,212 17 Tax expense Current tax 6,598 1,682,693 Total 6,598 1,682,693